Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

University of Cape Town

Rheinisch-westfaelische Technische Hochschule Aachen

Technische Universitat Ilmenau

Rheinisch-westfalische Technische Hochschule Aachen

Bitop Ag

Pharmed Artis Gmbh

Stefan Barth

Rainer Fischer

Andreas Reimann

Mehmet Kemal Tur

Torsten Klockenbring

Rolf Fendel

Dominika Maskus

Stephanie Kapelski

Michael Stöcker

Radoslav Mladenov

Sonja Schiffer

Ahmad Fawzi Hussain

Michael Fischer

Fatima Ferreira

Martin Hoffmann

Jens Müller

Beate Pawlowski

Eden Padayachee

Olusiji Alex Akinrinmade

Dmitrij Hristodorov

Sandra Jordaan

Grit Hehmann-Titt

Christoph Stein

Katharina Kolberg

Christiane Püttmann

Severin Schmies

Ulrich Wüllner

Thomas Nachreiner

Inga Neef

Lea Christin Schenke

Gernot Achatz

Fleury Augustin Nsole Biteghe

Theopilus Thepen

Christian Cremer

Michael Huhn

Elke Luger

Bernhard Stockmeyer

Jenny Fitting

Heike Bartsch De Torres

The present invention relates to fusion proteins which are capable of binding to phosphatidylserine comprising a phosphatidylserene binding ligand and a modified O6-alkylguanine-DNA alkyltransferase which is capable of autoconjugation to an O6-benzylguanine-modified label, the fusion proteins being capable of binding to phosphatidylserine on the surface of a cell undergoing apoptosis. The invention also relates to recombinant polypeptide precursors of the fusion proteins which comprise a secretion leader sequence, purification tag, protease cleavage site and the fusion protein. Also included in the scope of the invention are nucleic acids encoding the recombinant polypeptide precursor, vectors comprising the nucleic acids, host cells comprising the vectors, methods of production of the fusion proteins, kits and assays for detecting apoptosis.

Fusion proteins for the detection of apoptosis

The technology provided herein generally relates to novel specific photoimmuno-theranostics for the use in detection and elimination of skin cancer cells. The technology also relates to novel methods which generate homogeneous and specific photoimmuno-theranostics reagents in a simple, controlled and efficient way. This method combines molecular optical imaging, photodynamic therapy and immunotherapy using SNAP-tag technology.

Specific photoimmuno-theranostics for detection and elimination of skin cancer cells

Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferablyexotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.

Anti-CD89 cytotoxic complex

The technology provided herein relates to novel human antibodies againstparasites, in particular against the malaria parasite. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. toschizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Anti-plasmodium parasite antibodies

The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against() comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

Anti-parasitic complexes

The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof; to nucleic acid molecules encoding said recombinant hCFPs, vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.

Human cytolytic fusion proteins

A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.

Fusion protein to target and treat acute myeloid leukemia cells

The technology provided herein relates to novel immunoproteases suitable to induce apotosis in selected diseased target cells, comprising the serine protease granzyme M, and methods for using such cytolytic fusion proteins for the treatment of various diseases, in particular for the treatment of cancer.

Immunoproteases

Photoimmunoconjugates for use in photodynamic therapy

A compound formed from at least one component A comprising a binding domain for extra-cellular surface structures of a diseased proliferating cell that internalized upon binding of component A of said compound, and at least one component B, characterized in that component B is a polypeptide which amino acid sequence comprises a microtubule-associated protein (MAP) or comprises at least a partial sequence of the MAP, the partial sequence having maintained the binding function of the MAP to a microtubule.

Microtubule-modifying compound

The technology provided herein relates to novel human antibodies againstparasites, in particular against the malaria parasite. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. toschizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.

Granzyme B protease variants

A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.

Monoclonal antibody for the detection of SNAP/CLIP tag

A synthetic, soluble, endogenous complex formed from at least one component A and at least one component B, whereby component A comprises a binding domain for extra-cellular surface structures that internalize upon binding of component A of said complex, and component B has a constitutive catalytic kinase activity and effects cell biosynthesis/signalling including cell death after internalization. The complex allows to influence the growth and the physiology of cells. In particular said complex, nucleic acid molecules encoding it, cells transfected or transformed with these nucleic acid molecules are usable for the preparation of medicaments for the treatment of proliferative diseases, inflammatory diseases, allergies and autoimmune diseases.

Immunokinases

Subject of the invention is a compound, consisting of a targeting moiety which specifically binds to a disease related cell surface marker, a nucleic acid which specifically induces cell death and a linker, wherein the linker covalently links the targeting moiety to the nucleic acid. Subject of the invention are also medicaments comprising the compound and their use as a medicament for the treatment of diseases, including proliferative diseases.

Immuno-RNA-constructs

Growing community of inventors

Cape Town, South Africa

Stefan Barth